Journal Article

Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement

K. Schror

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_Q, pages Q54-Q59
Published in print December 2001 | ISSN: 1520-765X
Published online December 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90044-6
Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement

Show Summary Details

Preview

Patients with mechanical heart valve replacement require continuous antithrombotic treatment, mainly with oral anticoagulants of the coumarin type. Coumarins are currently applied in doses that generate an International Normalized Ratio (INR) between 2·5 and 3·5. A further increase in INR would improve the therapeutic outcome, but also would increase risk for bleeding. The combined use of coumarins at medium INR with antiplatelet drugs reduces the incidence of thromboembolic events at the risk of increased bleeding. Thus, the overall effect would appear to be the same.

Keywords: Aspirin; clopidogrel; oral anticoagulants; phenprocoumon; valve replacement; warfarin

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.